Iatrogenic addiction

Iatrogenic addiction means addiction caused by medical treatment, and Dopesick uses the concept to challenge the reassurance that carefully prescribed opioids posed little risk. The book traces how confident claims about safety met expanding pain-treatment standards and aggressive drug marketing, then sets medically driven exposure within a wider crisis of economic decline, stigma, and uneven access to care.

Definition and the Promise of Safety

In a 1996 training session for doctors, Purdue Pharma characterized doctor-caused addiction as exceptionally rare. The company’s medical director, David Haddox, told physicians that the risk of addiction when an opioid was taken as prescribed was one-half of one percent. The assurance did more than describe a risk estimate: it helped frame opioid prescribing as a safe and responsible response to pain, including pain that was not associated with terminal illness.

The book places that confidence against a longer history of medical use of opiates. Its account treats doctor-caused addiction not as an entirely new possibility, but as a danger made easy to discount when familiar drugs are presented through a new delivery system and accompanied by persuasive assurances. The term therefore marks a tension within medical care: treatment intended to relieve suffering can also expose patients to a drug-related risk that the prescriber or patient may not expect.

Pain Assessment and Expanding Prescribing

OxyContin’s 1996 introduction coincided with the adoption of pain as the fifth vital sign. Hospitals and accreditation bodies were developing standards that gave pain assessment and treatment a more formal place alongside measures such as blood pressure and temperature. At the same time, patient satisfaction surveys became more consequential to health-care providers, and pressure to achieve high ratings could encourage liberal treatment of pain.

In 1999, the Joint Commission on Accreditation of Healthcare Organizations approved mandatory pain-assessment and treatment standards. Purdue’s budget plan the following year identified those requirements as a commercial opportunity: the company proposed positioning itself as a leader in helping hospitals meet them through pain-assessment and pain-management materials. Its planned promotional materials included $300,000 in OxyContin-branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards bearing the fifth-vital-sign message. The overlap between clinical standards and product promotion is central to the book’s account: practices intended to recognize undertreated pain could also create new openings for opioid marketing and prescribing.

The apparent precision of pain scales concealed a further problem. Pain is subjective, and a numerical rating did not necessarily make it objectively comparable across patients or conditions. The book notes that reliance on such scales did not correlate with improved outcomes and had the effect of increasing opioid prescribing and abuse. A physician interviewed in the book recalled being told to prioritize pain more seriously and later recognizing that the approach had increased prescribing without adequate understanding of its consequences.

Medical Practice and Commercial Promotion

The book does not present prescribing as a matter of isolated decisions alone. When pharmaceutical advertising rules were loosened, spending on drug advertising rose from $360 million in 1995 to $1.3 billion in 1998, while companies increasingly used gifts to promote medicines to doctors. In rural small-town markets, Purdue used prescribing data to identify physicians already writing prescriptions for competing painkillers, then sent sales representatives to make a case for OxyContin’s potency and longer action. Doctors with higher prescribing potential received more visits and branded reminders for their offices.

Purdue’s representatives promoted the idea that OxyContin was safe and appropriate for people with conditions ranging from back pain and osteoarthritis to injury and trauma pain, not only for patients with cancer. The company’s safety claims thus operated alongside a deliberate sales strategy and an expanding set of medical contexts in which opioids were presented as a fitting response. Iatrogenic addiction, as the book uses the concept, belongs to that intersection of treatment, professional practice, and commercial influence—not simply to a story of individual patients making uninformed choices.

Wider Conditions and the Cost of Stigma

The book also resists treating medical exposure as a complete explanation for the epidemic. Shannon Monnat describes the collapse of work, rising disability, and the flood of painkillers as forces that converged; in her account, economic collapse supplied the kindling and opiates the spark. In rural counties affected by globalization, automation, and the decline of coal, the narrative records rising unemployment, food-stamp claims, and disability rates. These conditions help explain why a medical and commercial expansion of opioid supply had consequences beyond the clinic, without reducing addiction to any single cause.

The aftermath includes the difficulty of naming addiction and seeking help. When the reporting began in 2012 in the suburbs of Roanoke, Virginia, many interviewed families were too ashamed to speak publicly. Parents lacked online networks through which they might share practical support, and one mother described feeling branded as a failure. The book also shows how stigma could persist within recovery settings: people taking buprenorphine could be regarded by some twelve-step participants as not being clean, even though Narcotics Anonymous officially accepted medication-assisted treatment. That rejection could make sustained recovery harder precisely when a patient was seeking support.

These accounts connect the concept to the gaps between health care and criminal justice. Families, clinicians, volunteers, and people with addiction confront systems that do not reliably meet at the point where help is needed; meanwhile, shame can conceal the problem and delay support. Iatrogenic addiction names one consequential route into addiction, but the book’s larger argument is that exposure, economic circumstances, institutional responses, and stigma shape what follows—and whether treatment can reach people after harm has occurred.